# ETV5

Source: https://onco.cc/targets/etv5/  
OnCo record `etv5` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ETV5 (ETS translocation variant 5) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Pancreatic ductal adenocarcinoma, Neuroendocrine tumours and 4 more.

## Summary

Binds to DNA sequences containing the consensus nucleotide core sequence 5'-GGAA.-3'.

CIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Trametinib. Open Targets scores its association with cancer at 0.67 (direct and indirect evidence; datatypes literature 0.97, genetic association 0.20, somatic mutation 0.85). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Acute Myeloid Leukaemia.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: ETS variant transcription factor 5; ETS translocation variant 5
- Tags: cancer-genes-wave
- Symbol: ETV5
- Class: oncogene
- Biology: Binds to DNA sequences containing the consensus nucleotide core sequence 5'-GGAA.-3'. Location: Nucleus (UniProt). Locus 3q27.2 (HGNC).
- Where found: Lung cancer: CIViC evidence names this disease; Pancreatic ductal adenocarcinoma: CIViC evidence names this disease; Neuroendocrine tumours: Open Targets association 0.56 with neuroendocrine neoplasm (MONDO_0019496); Skin cancer: Open Targets association 0.52 with skin cancer (MONDO_0002898); Breast cancer: Open Targets association 0.52 with breast cancer (MONDO_0007254); Colorectal cancer: Open Targets association 0.51 with colorectal cancer (MONDO_0005575)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it an activating (Act) driver in 1 cohort; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:3494: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3494
- UniProt P41161: https://www.uniprot.org/uniprotkb/P41161/entry
- NCBI Gene 2119: https://www.ncbi.nlm.nih.gov/gene/2119
- Ensembl ENSG00000244405: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000244405

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/etv5.json